SSR is GlycoNex's second biosimilar program, a monoclonal antibody biosimilar candidate for an autoimmune disease. Initiated in February 2026 and developed entirely in-house — without external co-development partners — SSR represents the strategic next step from GlycoNex's denosumab biosimilar SPD8 program. The development thesis rests on four converging factors: the substantial commercial scale of the reference biologic class in immunology, the converging patent timelines of the reference originator products, alignment with GlycoNex's established antibody manufacturing platform, and operational continuity from SPD8's analytical method development, process scale-up, and quality systems. Following the biosimilar regulatory pathway, SSR advances through comparative analytical and functional characterization against the reference biologic rather than repeating full non-clinical safety evaluations. Process development is targeted for completion in the first half of 2028, with IND submission anticipated in the first half of 2029. Specific reference originator product and indication information is not disclosed publicly.
SSR
Biosimilar Candidate for an Autoimmune Disease
Building on the SPD8 biosimilar program, SSR extends GlycoNex's biosimilar capabilities into immunology — a monoclonal antibody biosimilar candidate for an autoimmune disease. Initiated February 2026, the program is developed in-house and advancing toward an IND submission targeted for the first half of 2029.
About SSR
Why this program
GlycoNex selected this biosimilar program based on four converging factors that together justify the in-house development investment.
A multi-billion-dollar therapeutic class
The reference biologic class represents a major therapeutic category in immunology, addressing diseases that affect tens of millions of patients globally. The commercial scale of the originator products demonstrates sustained demand and provides clear commercial validation for biosimilar development.
A converging patent landscape
The reference originator products are approaching key patent transition windows, opening a defined commercial entry opportunity that aligns with SSR's projected H1 2029 IND submission and downstream regulatory timeline.
Direct fit with GlycoNex's manufacturing platform
The molecular class — a humanized monoclonal antibody — aligns directly with GlycoNex's established antibody manufacturing platform. Cell line development, upstream process design, and analytical characterization leverage capabilities already in place.
Operational continuity from SPD8
Analytical methods, process scale-up protocols, and quality systems built through the SPD8 denosumab biosimilar program provide an established foundation that reduces development risk and accelerates the SSR timeline.
Following the biosimilar regulatory pathway
SSR advances through the biosimilar regulatory pathway, with comparative analytical and functional characterization against the reference biologic as the core development strategy. This pathway leverages the extensive clinical safety and efficacy database of the reference originator product, allowing biosimilar development to focus on demonstrating analytical and functional similarity rather than repeating full non-clinical and clinical safety programs.
The program is structured around full alignment with ICH Q6B principles and the regulatory expectations of Taiwan's TFDA and other major regulatory authorities. Comparative analytical characterization includes structural, physicochemical, and functional profiling against the reference biologic. The development plan is designed to support a robust biosimilar regulatory dossier upon IND submission.
Development pathway
SSR is in active preclinical development. The program timeline reflects current planning assumptions; actual milestones are subject to scientific, regulatory, and operational factors.
Building on the SPD8 foundation
SSR's in-house development model is enabled by the operational foundation built through GlycoNex's SPD8 denosumab biosimilar program. SPD8's analytical method development, process scale-up, and quality systems — refined through co-development with Mitsubishi Gas Chemical since 2018 and validated through the October 2025 Phase 3 enrollment completion — provide a tested framework that SSR's development team leverages directly.
This continuity allows GlycoNex to advance SSR without external co-development partners. The SPD8 program demonstrated that GlycoNex's biosimilar capability extends from analytical characterization through Phase 3 clinical execution; SSR applies that same capability to immunology.
View SPD8 program details →Development status
In-house development at this stage
GlycoNex is developing SSR entirely in-house. The program is not actively seeking external co-development partners at this preclinical stage.
Inquiries from companies interested in future commercialization rights or other later-stage collaboration structures are welcomed and can be directed to the GlycoNex business development team.
Extending GlycoNex's biosimilar capability into immunology
SSR represents the next phase of GlycoNex's biosimilar development — an in-house biosimilar program building on the SPD8 foundation.